Skip to content
Clinical Trials – home
LatviaBack to Latvia

Clinical trials in Jelgava – page 12

210 clinical trials in Jelgava, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Jelgava at a glance
210
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

210 trials in Jelgava

Open in trial search

Obesity

Not recruiting

Study of Semaglutide and Glucagon Effects on Energy Expenditure and Glucose Levels in Healthy Volunteers

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · Healthy volunteers
  • Substances:Semaglutide
  • Sponsor:Pauls Stradins Clinical University Hospital

Study on the Effects of Bexicaserin for Treating Seizures in Children and Adults with Dravet Syndrome

Investigational
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bexicaserin hydrochloride
  • Sponsor:Longboard Pharmaceuticals Inc.

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Study of TX000045 for Pulmonary Hypertension in Heart Failure Patients with Preserved Ejection Fraction

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:TX000045
  • Sponsor:Tectonic Therapeutic Inc.

Study on the Effects of Mosliciguat for Patients with Pulmonary Hypertension Linked to Interstitial Lung Disease

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Bladder cancer

Not recruiting

Study on UGN-102 (Mitomycin) for Treating Low Grade Non-Muscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Study of single-dose oritavancin safety and tolerability in children with acute bacterial skin and skin structure infections

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:0–17 years
  • Substances:Aztreonam
  • Sponsor:Melinta Therapeutics LLC

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Bladder cancer

Not recruiting

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Poloxamer 407
  • Sponsor:Urogen Pharma Ltd.

Abdominal infection+3

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Other cities in Latvia

The busiest research cities in the country

All 18 cities in Latvia

Clinical research in Jelgava

What the registry says about research in the country

01 Diabetes Management Studies

Clinical investigations focusing on type 2 diabetes management through combination therapy approaches. Research evaluates the effectiveness of gliclazide MR when combined with existing treatments.

  • Treatment Optimization
  • Glycemic Control
  • Combination Therapy

Studies aim to improve blood sugar control in patients not achieving optimal results with current medications.

02 Diabetic Eye Disease Research

Groundbreaking research examining the impact of semaglutide on diabetic retinopathy in patients with type 2 diabetes. This long-term safety study evaluates treatment effects on eye health.

  • Retinopathy Development
  • Disease Progression
  • Ophthalmologic Assessment

The research includes standardized ophthalmic evaluations to monitor disease progression and treatment outcomes.

03 Therapeutic Safety Studies

Post-authorization safety assessments conducted under European Medicines Agency oversight, focusing on long-term effects of diabetes treatments.

  • Safety Monitoring
  • Long-term Outcomes
  • Treatment Effects

These studies contribute to understanding the complete safety profile of new diabetes medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.